

Pneumococcal Vaccines

Arthur Reingold, MD

Pneumococcal Vaccines Work Group Chair

Advisory Committee on Immunization Practices

October 26, 2017




Pneumococcal Vaccines Work Group

- ACIP members
 - Arthur Reingold (Chair)
 - Nancy Bennett
 - Allison Kempe
 - Paul Hunter
 - Grace Lee
- Ex officio members
 - Tina Mongeau (FDA)
 - Lucia Lee (FDA)
- CDC lead
 - Tamara Pilishvili (NCIRD)
- Liaison representatives and consultants
 - Lorry Rubin (AAP)
 - Carol Baker (AAP)
 - Mark Sawyer (AAP/CIOD)
 - Rick Zimmerman (AAFP)
 - Chris Lupold (AAFP)
 - Sandra Fryhofer (ACP)
 - Jane Zucker (AIM)
 - William Schaffner (NFID)
 - Monica Farley (DVA)
 - Jeffrey Duchin (U. of Washington)
 - Keith Klugman (Gates Foundation)
 - Kathy Neuzil (IDSA)

Pneumococcal Vaccines Work Group: Terms of Reference

- Review current data on efficacy, effectiveness, immunogenicity, and cost-effectiveness of pneumococcal vaccines
- Review current recommendations considering up-to-date evidence, including epidemiological studies conducted post-licensure, and assess strength of the evidence
- Revise or update recommendations for pneumococcal vaccine use, as needed

PCV13 recommendations over time



ACIP August 2014: PCV13 recommended for adults 65 years and older

- Work Group and ACIP Conclusions
 - Short term: recommendation for universal PCV13 use is warranted
 - Long term: continued herd effects may limit the utility of a universal recommendation
 - Magnitude of indirect effects unknown
 - Uncertainty around the burden of vaccine preventable non-bacteremic pneumonia
 - Recommendation for re-evaluation and revision as needed of routine PCV13 use among adults 65 years and older in 2018

Re-evaluation of PCV13 for adults 65 years and older recommendation

- Monitor pneumococcal disease and vaccine impact in the target population of adults 65 years and older
- Monitor indirect vaccine effects on pneumococcal disease trends among PCV13-naïve adults (19-64 years old without PCV13 indications)
- Routinely update ACIP on direct and indirect effects and pneumococcal disease trends among adults leading up to 2018 discussions

October 2016 ACIP Meeting

- Updated on changes in invasive pneumococcal disease following PCV13 introduction in children
 - Indirect (herd) effects among adults
 - No data on direct effects of PCV13 use among adults
- Presented outline of research agenda to inform potential policy change in 2018

Today's Pneumococcal Vaccines Session

Outline

- Pneumococcal colonization studies
 - Among children <5 years of age
 - Stepy Thomas, GA Emerging Infections Program, VA Medical Center
 - Among adults ≥ 65 years old
 - Fernanda Lessa, NCIRD
- Changes in invasive pneumococcal disease in children, adults, and adults living with HIV
 - Almea Matanock, NCIRD
- Progress of research to inform potential policy reconsideration in 2018 for PCV13 use among adults
 - Tamara Pilishvili, NCIRD

Discussion Questions for Today's Pneumococcal Vaccines Session

- Is the proposed research agenda appropriate to help determine if potential policy change is needed in 2018?
- What additional information will the committee need to help determine in 2018 whether continued PCV13 use in adults 65 years and older is warranted?